MedPlus Health Services: Subsidiary Optival Health Solutions Receives Drug License Suspension Orders in Karnataka

Medplus Health Services has informed the stock exchanges that its subsidiary, Optival Health Solutions Private Limited, has received suspension orders for drug licenses of stores situated in Karnataka. The disclosure was made to BSE Limited and National Stock Exchange of India Limited under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The orders were issued by the Assistant Director, Drugs Control Administration, Bangalore Circle - 3, Bangalore, Karnataka. The regulatory action was taken under Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945.

Details of Suspension Orders

The suspension orders affect stores with varying durations and potential financial impacts:

Parameter	Details
Location	24th Main 4th T Block Jayanagar, Karnataka
Suspension Duration	Five days
Potential Revenue Impact	Rs 5.39 lacs
Authority	Assistant Director, Drugs Control Administration, Circle-3 Bangalore, Karnataka
Date of Receipt	April 21, 2026

Regulatory Compliance

The suspension order was issued under Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945. The company has ensured full transparency by making the information available on its website at www.medplusindia.com , as well as on the websites of BSE Limited and National Stock Exchange of India Limited.

The disclosure was signed by Manoj Kumar Srivastava, Company Secretary & Compliance Officer of MedPlus Health Services Limited, on April 22, 2026, ensuring compliance with regulatory requirements for timely disclosure of material events.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.77%	+0.29%	+3.73%	+11.09%	+5.27%	-21.98%

MedPlus Health Services Limited has informed stock exchanges about multiple regulatory actions affecting its subsidiary operations. The company disclosed that Optival Health Solutions Private Limited, a subsidiary, has received suspension orders for drug licenses across multiple stores in different states.

Latest Regulatory Actions

The company has received two additional suspension orders following the earlier action in Telangana. The latest orders affect stores in Andhra Pradesh and Odisha, with varying suspension periods and financial impacts.

Authority:	Store Location	Suspension Period	Revenue Impact
Assistant Director, Drugs Control Administration, Eluru & West Godavari District, AP	Ameenapeta Eluru, Andhra Pradesh	Seven days	Rs 5.85 lacs
Deputy Drugs Controller, Bhubaneswar, Odisha	Market building Saheednagar, Odisha	Two days	Rs 0.96 lacs
Assistant Director, Drugs Control Administration, Mahabubnagar, Telangana	Jadcherla, Telangana	Two days	Rs 0.28 lacs

Cumulative Financial Impact

The combined effect of all three suspension orders represents a significant operational disruption for the subsidiary. The total potential revenue loss across all affected stores amounts to Rs 6.81 lacs, with the Andhra Pradesh store suspension contributing the largest impact due to its seven-day duration.

Regulatory Compliance Framework

All violations fall under Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945. The disclosures are being made under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, in compliance with SEBI circulars dated July 13, 2023, and December 31, 2024.

Corporate Communication

The information has been made available on the company's website at www.medplusindia.com and will also be accessible on BSE and NSE websites. The latest disclosure was signed by Manoj Kumar Srivastava, Company Secretary & Compliance Officer, on April 15, 2026.